Abstract
In recent times, bitter melon extract (BME) has gained significant attention for its anticancer efficacy against various malignancies. In this issue, Sur and colleagues show that BME prevents the development of 4-nitronitroquinoline 1-oxide–induced oral dysplasia and squamous cell carcinoma (SCC) in an immunocompetent mouse model. Importantly, gene ontology and pathway analyses revealed an elevated expression of s100a9, IL23a, IL1β, and PDCD1/PD1 of immune system during oral cancer development, which was significantly suppressed by BME. Overall, this study demonstrates the potential clinical benefits of BME in preventing and delaying the progression of oral dysplasia to SCC.Cancer Prev Res; 11(4); 1–2. ©2018 AACR.
See related article by Sur et al., p. 191
- Received November 21, 2017.
- Revision received December 14, 2017.
- Accepted December 15, 2017.
- ©2018 American Association for Cancer Research.
Published OnlineFirst March 20, 2018
doi: 10.1158/1940-6207.CAPR-17-0379
